TuHURA Biosciences (NASDAQ:HURA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of TuHURA Biosciences (NASDAQ:HURA) from a hold rating to a sell rating in a report released on Tuesday.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $9.00.

TuHURA Biosciences Trading Up 1.7%

Shares of NASDAQ:HURA opened at $1.48 on Tuesday. The company has a 50 day moving average of $1.42 and a 200 day moving average of $1.60. The stock has a market cap of $93.78 million, a P/E ratio of -2.34 and a beta of -0.32. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.44.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Institutional Trading of TuHURA Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of TuHURA Biosciences during the 3rd quarter valued at $26,000. JPMorgan Chase & Co. purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at $27,000. Wells Fargo & Company MN raised its position in shares of TuHURA Biosciences by 109.0% during the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after buying an additional 19,931 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $30,000. Finally, Invesco Ltd. purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.